1 year ago

The Deal


Despite falling deal

Despite falling deal numbers it’s been a good year for Life Sciences, with some high-profile investments and an upsurge in both deals and amount invested for seed-stage businesses. Deal Numbers, Technology Sub-Sectors This analysis is based on weighted sector figures, as detailed in the methodology. 360 Materials Technology 320 280 Other Tech/IP-based Businesses Nanotechnology Clean Technology Hardware Medical Technology Life Sciences Software 240 200 160 120 80 40 2011 2012 2013 2014 2015 2016 14

Life Sciences Deal Numbers and Amount Invested This analysis is based on double counted sector figures. Early-stage Life Sciences storms ahead. £500m £400m £300m Amount Invested Seed Venture Growth Despite an overall dip in deal numbers and amount invested, investment into Life Sciences is booming. Seed-stage investments into the sector have weathered the investment slump well with deal numbers increasing every year, up 19% from 2015. The amount invested has also grown continuously — this year by a staggering 182% to £202m. £200m £100m Deal Numbers Life Sciences make a strong showing wth big deals. There was also cause for celebration amongst later-stage Life Sciences companies. Oxford Nanopore, Kymab, Autolus, F2G, and Mission Therapeutics each raised over £40m, putting their fundraisings firmly in the 20 biggest of the year. Woodford Investment Management contributed to all but one of these rounds. 40 30 20 19% 10 increase in Life Sciences deal numbers at the seed-stage. 2011 2012 2013 2014 2015 2016 15

latest digital edition of France unquote
Equity Crowdfunding
atest digital edition of Nordic unquote
Preqin Special Report: Cleantech
Download as PDF -